Decoy-20 is under clinical development by Indaptus Therapeutics and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. According to GlobalData, Phase I drugs for Metastatic Adenocarcinoma of The Pancreas have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Decoy-20’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Decoy-20 overview

Decoy-20 is under development for the treatment of solid tumors including colorectal cancer, bladder carcinoma, breast cancer, cervical cancer, non-Hodgkin lymphoma, adenoid cystic carcinoma, urothelial cancer, squamous cell carcinoma of the head and neck, adenocarcinoma of the pancreas, non-small cell lung cancer and hepatocellular carcinoma-associated HBV infection and human immunodeficiency virus (HIV) infection. It comprises of a single strain of killed and intact, non-pathogenic gram bacteria with reduced LPS-endotoxin activity. it is administered through intravenous route.

Indaptus Therapeutics overview

Indaptus Therapeutics (Intec Pharma) is a biopharmaceutical company that develops drugs based on its proprietary Accordion Pill technology. The company’s product pipeline includes AP-CD/LD, a gastric-retentive drug used for treating Parkinson’s disease; AP-THC and AP-CBD, cannabinoid treatments for multiple pain indications such as low back pain, neuropathic pain and fibromyalgia. Its proprietary technology platform Accordion Pill, an oral drug delivery system is designed to improve the ability of existing drugs and drugs in development utilizing a gastric retention and specific release mechanism. The company works in collaboration with Merck Sharp and Dohme, LTS Lohmann Therapie-Systeme AG and other pharmaceutical companies to develop novel delivery systems for advancing its pipeline drug candidate. Intec Pharma is headquartered in Jerusalem, Israel.

For a complete picture of Decoy-20’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.